Key Market Indicator:
F&G: 40
25.233,35 NASDAQ · 48.573,00 DOW · 6.841,40 S&P · 4.299,43 Gold · 61,01 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
CA64082X2032
Filter zurücksetzen
© Newsfile
13.12.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Announces Proposed Amendment to Warrants
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that the Compa...
Themefolio
Profiler
Peergroup
© Newsfile
24.11.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates
Article
News Preview
Expanded CONNECT SCI Study data demonstrated unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic spinal cord injuryCompleted a U.S. Food and Drug Administration (FDA) Type C meeting in September; FDA confirmed that multiple regulatory routes are available to support approval of NVG-291...
Themefolio
Profiler
Peergroup
© Newsfile
24.11.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury
Article
News Preview
Week 16 follow-up data, coupled with blinded exit interviews conducted up to 364 days after the study period, confirm durable and wide-ranging upper and lower-body improvements compared to placeboParticipant-reported outcomes highlight substantial improvements in bladder control and muscle spasticity compared to placeboStatistically significan...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Newsfile
19.11.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it has co...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
18.11.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that...
Themefolio
Profiler
Peergroup
© Newsfile
26.08.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders
Article
News Preview
Announced unprecedented Phase 1b/2a topline results in chronic spinal cord injury NVG-291 is the first pharmacologic candidate to demonstrate statistically significant improvement in corticospinal connectivity with clinically meaningful functional gainsOngoing comprehensive analysis of NVG-291's efficacy profile will support upcoming regulatory dis...
Themefolio
Profiler
Peergroup
© Newsfile
21.08.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury
Article
News Preview
Demonstrated significant hearing restoration in blast-induced sensorineural hearing loss modelsPromoted significant functional recovery and axonal regeneration in peripheral nerve injury modelsReinforced NVG-291's broad therapeutic potential with new data across three distinct injury modelsVancouver, British Columbia--(Newsfile Corp. - August 21, 2...
Themefolio
Profiler
Peergroup
© Newsfile
17.07.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Announces Leadership Transition to Support Strategic Growth and Expansion
Article
News Preview
Chairman Dr. Adam Rogers Appointed Interim CEO Following Landmark Positive Chronic Spinal Cord Injury Trial ResultsVancouver, British Columbia--(Newsfile Corp. - July 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) (the "Company"), a clinical-stage biotechnology company developing innovative therapies for spinal cord injury (...
Themefolio
Profiler
Peergroup
© Newsfile
07.07.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 7, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developing innovative treatments for spinal cord injury (SCI) and other neurological conditions, today provided a quarterly update with respect to the C...
Themefolio
Profiler
Peergroup
© Newsfile
03.07.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth
Article
News Preview
Dr. Adam Rogers appointed chair as company advances toward key milestones following positive topline chronic cohort results of Phase 1b/2a CONNECT SCI StudyVancouver, British Columbia--(Newsfile Corp. - July 3, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative treatments f...
Themefolio
Profiler
Peergroup
© Newsfile
01.07.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 1, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeutics, today announced that Daniel Mikol, MD, Ph.D., has resigned from his position as Chief Medical Officer in order to pursue new opportunities. Randall Ka...
Themefolio
Profiler
Peergroup
© Newsfile
18.06.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeutics, today announced the appointment of Randall Kaye, MD, to the role of Chief Medical Advisor. Dr. Kaye, a current member of NervGen's Board of Directors...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
02.06.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
Canadian Investment Regulatory Organization Trade Resumption - NGEN
Article
News Preview
VANCOUVER, BC, June 2, 2025 /CNW/ - Trading resumes in: Company: NervGen Pharma Corp. TSX-Venture Symbol: NGEN All Issues: No Resumption (ET): 10:24:39 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
Canadian Investment Regulatory Organization Trading Halt - NGEN
Article
News Preview
VANCOUVER, BC, June 2, 2025 /CNW/ - The following issues have been halted by CIRO Company: NervGen Pharma Corp. TSX-Venture Symbol: NGEN All Issues: No Reason: Single Stock Circuit Breaker Halt Time (ET): 10:19:39 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading ha...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
Canadian Investment Regulatory Organization Trade Resumption - NGEN
Article
News Preview
VANCOUVER, BC, June 2, 2025 /CNW/ - Trading resumes in: Company: NervGen Pharma Corp. TSX-Venture Symbol: NGEN All Issues: No Resumption (ET): 10:15:54 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
Canadian Investment Regulatory Organization Trading Halt - NGEN
Article
News Preview
VANCOUVER, BC, June 2, 2025 /CNW/ - The following issues have been halted by CIRO Company: NervGen Pharma Corp. TSX-Venture Symbol: NGEN All Issues: No Reason: Single Stock Circuit Breaker Halt Time (ET): 10:10:54 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading ha...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
Canadian Investment Regulatory Organization Trade Resumption - NGEN
Article
News Preview
VANCOUVER, BC, June 2, 2025 /CNW/ - Trading resumes in: Company: NervGen Pharma Corp. TSX-Venture Symbol: NGEN All Issues: No Resumption (ET): 9:43:17 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO i...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
Canadian Investment Regulatory Organization Trading Halt - NGEN
Article
News Preview
VANCOUVER, BC, June 2, 2025 /CNW/ - The following issues have been halted by CIRO Company: NervGen Pharma Corp. TSX-Venture Symbol: NGEN  All Issues: No Reason: Single Stock Circuit Breaker Halt Time (ET): 9:38:17 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading ha...
Themefolio
Profiler
Peergroup
© PR Newswire
23.05.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
Canadian Investment Regulatory Organization Trade Resumption - NGEN
Article
News Preview
VANCOUVER, BC, May 23, 2025 /CNW/ - Trading resumes in: Company: NervGen Pharma Corp. TSX-Venture Symbol: NGEN All Issues: No Resumption (ET): 10:18:14 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO...
Themefolio
Profiler
Peergroup
© PR Newswire
23.05.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
Canadian Investment Regulatory Organization Trading Halt - NGEN
Article
News Preview
VANCOUVER, BC, May 23, 2025 /CNW/ - The following issues have been halted by CIRO Company: NervGen Pharma Corp. TSX-Venture Symbol: NGEN All Issues: No Reason: Single Stock Circuit Breaker Halt Time (ET): 10:13:14 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading ha...
Themefolio
Profiler
Peergroup
© Newsfile
21.05.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative therapeutics, today announced that topline results from the chronic cohort of the ongoing Phase 1b/2a study of NVG-291 will be presented as an oral presentati...
Themefolio
Profiler
Peergroup
© Newsfile
16.05.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 16, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative therapeutics, today announced that it has granted 600,000 incentive stock options (the "Options") to directors and employees of the company. The Options are e...
Themefolio
Profiler
Peergroup
© Newsfile
15.05.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates
Article
News Preview
Completed last subject, last visit in the chronic cohort, data readout targeted for early June 2025Vancouver, British Columbia--(Newsfile Corp. - May 15, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuro-reparative therapeutics, today reported its financial and operational...
Themefolio
Profiler
Peergroup
© Newsfile
07.05.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
Article
News Preview
All resolutions submitted for approval were passed by shareholdersVancouver, British Columbia--(Newsfile Corp. - May 7, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, announces the results of its Annual General Meeting of Shareholders ("AGM") held on...
Themefolio
Profiler
Peergroup
© Newsfile
21.04.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 21, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto, ON. Mike Kelly, President & CEO...
Themefolio
Profiler
Peergroup
© Newsfile
09.04.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Provides Quarterly "At-The-Market" Equity Program Update
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 9, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today provided a quarterly update with respect to the Company's previously announced at-the-market equity program (the...
Themefolio
Profiler
Peergroup
© Newsfile
03.04.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Reports 2024 Year-End Financial Results and Provides Business Updates
Article
News Preview
Completed enrollment in the chronic cohort and commenced enrollment in the subacute cohort of its Phase 1b/2a clinical trial for lead drug candidate, NVG-291, in spinal cord injury (SCI)Initiated an expanded access protocol for NVG-291 for individuals with SCI who have participated in a NervGen clinical trial and meet specific eligibility criteriaP...
Themefolio
Profiler
Peergroup
© Newsfile
31.03.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Initiates Expanded Access Policy
Article
News Preview
The U.S. Food and Drug Administration (FDA) informed the company that an expanded access protocol for NVG-291 may proceedThis news release constitutes a "designated news release" for the purposes of NervGen's prospectus supplement dated December 19, 2024 to its short form base shelf prospectus dated November 25, 2024.Vancouver, British Columbia--(N...
Themefolio
Profiler
Peergroup
© Newsfile
15.03.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 14, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that it has granted 545,000 incentive stock options (the "Options") to employees and consultants of the company, including 100,000...
Themefolio
Profiler
Peergroup
© Newsfile
05.03.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma to Present at the Virtual Life Science Investor Forum
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 5, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that Mr. Mike Kelly, President & CEO, will be presenting at the Virtual Life Sciences Investor Forum hosted by OTC Markets Group...
Themefolio
Profiler
Peergroup
© Newsfile
18.02.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that it has granted 627,200 incentive stock options to the company's employees, including 505,200 to the company's Officers, exe...
Themefolio
Profiler
Peergroup
© Newsfile
06.02.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that the first subject has been enrolled and dosed in the subacute cohort of its Phase 1b/2a proof-of-concept, double-blind, rand...
Themefolio
Profiler
Peergroup
© Newsfile
29.01.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Article
News Preview
Vancouver, Canada--(Newsfile Corp. - January 29, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that Mr. Mike Kelly, President & CEO, will be participating in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences...
Themefolio
Profiler
Peergroup
© Newsfile
02.01.2025
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
Article
News Preview
Topline data from the chronic cohort is expected in Q2 2025Institutional Review Board (IRB) protocol amendment changes approved, and screening has been initiated for subacute cohortThis news release constitutes a "designated news release" for the purposes of NervGen's prospectus supplement dated December 19, 2024 to its short form base shelf prospe...
Themefolio
Profiler
Peergroup
© Newsfile
20.12.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Announces "At-The-Market" Equity Program
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, is pleased to announce that it has established an at-the-market equity program (the "ATM Program") that allows...
Themefolio
Profiler
Peergroup
© Newsfile
14.11.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates
Article
News Preview
Target enrollment in the chronic cohort of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury (SCI) is approaching completionNVG-300 preclinical test-of-concept studies in ischemic stroke, amyotrophic lateral sclerosis (ALS) and SCI underwayVancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - NervGen Pha...
Themefolio
Profiler
Peergroup
© Newsfile
07.11.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma to Present at the Stifel 2024 Healthcare Conference
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, announced today that Mr. Mike Kelly, President & CEO, will be participating in a fireside chat at the Stifel 2024 Healthcare Conference on Mo...
Themefolio
Profiler
Peergroup
© Newsfile
30.09.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
Article
News Preview
Target enrollment in the chronic cohort close to completionVancouver, British Columbia--(Newsfile Corp. - September 30, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that target enrollment of the chro...
Themefolio
Profiler
Peergroup
© Newsfile
20.09.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., NervGen's Chief Medical Officer, will give an oral presentation...
Themefolio
Profiler
Peergroup
© Newsfile
16.09.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma to Present at the 63rd International Spinal Cord Society Annual Scientific Meeting
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 16, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., NervGen's Chief Medical Officer, will present at the 63rd Inter...
Themefolio
Profiler
Peergroup
© Newsfile
27.08.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting at the H.C. Wainwright 26th Annual...
Themefolio
Profiler
Peergroup
© Newsfile
22.08.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Reports Q2 2024 Financial Results and Operational Updates
Article
News Preview
Targeting to complete enrollment in the Phase 1b/2a chronic cohort in Q3 2024Protocol being amended to enhance enrollment and lessen burden on participants in the subacute cohortNVG-300 advanced into preclinical proof-of-concept studies in ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI)Vancouver, British Columbia--...
Themefolio
Profiler
Peergroup
© Newsfile
06.08.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting at the Canaccord Genuity 44th Annual...
Themefolio
Profiler
Peergroup
© Newsfile
02.08.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 2, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 30,000 incentive stock options to employees of the company and 15,000 incen...
Themefolio
Profiler
Peergroup
© Newsfile
22.07.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Appoints Neil Klompas to Board of Directors
Article
News Preview
Seasoned pharmaceutical executive with extensive experience in high-growth life sciences companies joins NervGenLeadership appointment supports the company's mission to advance NVG-291 after the completion of the ongoing Phase 1b/2a studyVancouver, British Columbia--(Newsfile Corp. - July 22, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF)...
Themefolio
Profiler
Peergroup
© Newsfile
25.06.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage
Article
News Preview
New molecule demonstrates efficacy in a challenging SCI modelExpanding pipeline into new indications of ischemic stroke and ALSVancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous sy...
Themefolio
Profiler
Peergroup
© Newsfile
20.06.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting a corporate update at the 2nd Annual...
Themefolio
Profiler
Peergroup
© Newsfile
07.06.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 950,000 incentive stock options to directors and consultants of the company e...
Themefolio
Profiler
Peergroup
© Newsfile
05.06.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
Article
News Preview
All resolutions submitted for approval were passed by shareholdersGlenn Ives appointed as Chair of the BoardJohn Ruffolo appointed as Chair of the Audit CommitteeVancouver, British Columbia--(Newsfile Corp. - June 5, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutio...
Themefolio
Profiler
Peergroup
© Newsfile
17.05.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., Chief Medical Officer, will be presenting two posters at the upcoming...
Themefolio
Profiler
Peergroup
© Newsfile
16.05.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates
Article
News Preview
Target for completing enrollment of the chronic cohort in the Phase 1b/2a clinical trial moved to Q3 2024Subacute cohort protocol being amended to enhance feasibility and lessen burden on participantsCA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Vancouver, British Columbia--(Newsfile Corp....
Themefolio
Profiler
Peergroup
© Newsfile
07.05.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Files Management Information Circular and Announces Board of Directors Transition
Article
News Preview
Bill Radvak to transition to Board Advisor following decision to not stand for re-election to NervGen's Board of DirectorsAnnual General Meeting of Shareholders to be held on June 4, 2024Vancouver, British Columbia--(Newsfile Corp. - May 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical-stage biote...
Themefolio
Profiler
Peergroup
© Newsfile
25.04.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Engages Russo Partners LLC to Provide Public Relations Services
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has engaged Russo Partners LLC ("Russo Partners"), a New York base...
Themefolio
Profiler
Peergroup
© Newsfile
17.04.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
Article
News Preview
Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NVG-291 in spinal cord injuryVancouver, British Columbia--(News...
Themefolio
Profiler
Peergroup
© Newsfile
28.03.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Completes $23 Million Bought Deal Financing
Article
News Preview
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.Vancouver, British Columbia--(Newsfile Corp. - March 28, 2024) - NervGen Pharma Corp. (TSXV: NGEN) ("NervGen" or the "Company") is pleased to announce the closing of its previously announced public offering (the "Offering") including the full exe...
Themefolio
Profiler
Peergroup
© Newsfile
21.02.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 21, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has been recognized by the TSX Venture Exchange as a 2023 Top 50 Company. The 2024 TSX Venture 50™ showc...
Themefolio
Profiler
Peergroup
© Newsfile
20.02.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that it has granted incentive stock options to the Company's employees, including 505,200 to t...
Themefolio
Profiler
Peergroup
© Newsfile
15.02.2024
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
Article
News Preview
On track to complete enrollment of the chronic cohort in Q2 2024Data readout from chronic cohort expected in Q3 2024Planning underway to make NVG-291 available to placebo-treated subjects following cohort completion Vancouver, British Columbia--(Newsfile Corp. - February 15, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stag...
Themefolio
Profiler
Peergroup
© Newsfile
09.11.2023
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates
Article
News Preview
Phase 1a/2b clinical trial of NVG-291 underway with dosing of individuals with spinal cord injury; results from chronic cohort expected in mid-2024 Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NVG-291 in spinal cord injurySeasoned financial industry executive, John Ruffolo, appointed to BoardVancouver, British Colum...
Themefolio
Profiler
Peergroup
© Newsfile
08.11.2023
ISIN: CA64082X2032
Nervgen Pharma Corp.
NGEN
LISTED
TSX
Neuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on 'Remarkable People' Podcast Hosted by Tech Luminary Guy Kawasaki
Article
News Preview
Dr. Silver's life work, culminating in NervGen's NVG-291, is currently in a Phase 1b/2a clinical trial for individuals with spinal cord injury.Vancouver, British Columbia--(Newsfile Corp. - November 8, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the trea...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 14.12.2025, Calendar Week 50, 348th day of the year, 17 days remaining until EoY.